Novartis cardiovascular news

In its 4Q12 earnings, Novartis said it received a subpoena from the U.S. Attorney's Office for the Western District of Kentucky seeking documents related to the company's marketing of Tekturna aliskiren and aliskiren-containing combination products. Novartis said it is cooperating with the investigation, which is "civil and criminal in nature." Novartis markets aliskiren as Tekturna in the U.S. and as Rasilez in the EU to treat hypertension. The company also markets Tekamlo aliskiren/amlopipene in the U.S. for hypertension. Tekturna had $81 million in U.S. revenues in 4Q12. ...